Matinas BioPharma Holdings Inc. (MTNB) market price of $0.89 offers the impression of an exciting value play

At the end of the latest market close, Matinas BioPharma Holdings Inc. (MTNB) was valued at $0.87. In that particular session, Stock kicked-off at the price of $0.86 while reaching the peak value of $0.89 and lowest value recorded on the day was $0.85. The stock current value is $0.89.

Recently in News on September 15, 2020, Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG). – FDA Agreement to Move Directly into Phase 3 -. You can read further details here

Matinas BioPharma Holdings Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.3900 on 01/02/20, with the lowest value was $0.4900 for the same time period, recorded on 04/07/20.

Matinas BioPharma Holdings Inc. (MTNB) full year performance was 22.54%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Matinas BioPharma Holdings Inc. shares are logging -64.08% during the 52-week period from high price, and 82.53% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.49 and $2.49.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 509339 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Matinas BioPharma Holdings Inc. (MTNB) recorded performance in the market was -61.67%, having the revenues showcasing 9.78% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 172.37M, as it employees total of 21 workers.

Specialists analysis on Matinas BioPharma Holdings Inc. (MTNB)

During the last month, 4 analysts gave the Matinas BioPharma Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 0.8128, with a change in the price was noted -0.0256. In a similar fashion, Matinas BioPharma Holdings Inc. posted a movement of -2.78% for the period of last 100 days, recording 2,204,706 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for MTNB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Trends and Technical analysis: Matinas BioPharma Holdings Inc. (MTNB)

Raw Stochastic average of Matinas BioPharma Holdings Inc. in the period of last 50 days is set at 71.25%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 90.57%. In the last 20 days, the company’s Stochastic %K was 85.00% and its Stochastic %D was recorded 87.15%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -61.67%. Additionally, trading for the stock in the period of the last six months notably improved by 27.88%, alongside a boost of 22.54% for the period of the last 12 months. The shares increased approximately by 2.03% in the 7-day charts and went down by 11.77% in the period of the last 30 days. Common stock shares were driven by 9.78% during last recorded quarter.